aUniversity of Washington, Seattle, WA;
bUniversity of Manitoba, Winnipeg, Canada;
cUniversity of California San Diego, San Diego, CA;
dJohns Hopkins School of Medicine, Baltimore, MD;
eUniversity of Alabama at Birmingham, Birmingham, AL;
fUniversity of North Carolina at Chapel Hill, Chapel Hill, NC;
gFenway Health, Boston, MA;
hCase Western Reserve University, Cleveland, OH; and
iUniversity of California, San Francisco, San Francisco, CA.
Correspondence to: Adrienne E. Shapiro, MD, PhD, Departments of Global Health and Medicine, Division of Allergy and Infectious Diseases, Box 359927, 325 9th Avenue, Seattle, WA 98102 (e-mail: [email protected]).
Funding for this study and for CNICS came from the US National Institutes of Health: National Institute of Allergy and Infectious Diseases (NIAID) [CNICS R24 AI067039; UW CFAR NIAID Grant P30 AI027757; UAB CFAR Grant P30 AI027767; UNC CFAR Grant P30 AI50410; UCSD CFAR Grant P30 AI036214; Case Western Reserve University CFAR Grant P30 AI036219; Fenway Health/Harvard CFAR Grant P30 AI060354; UCSF CFAR Grant P30 AI027763; and JHU CFAR Grant P30 AI094189] and the National Institute on Drug Abuse (NIDA) [R01DA047045]. The funders had no role in the design, conduct, or reporting of the study.
The authors have no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
A.E.S. and R.A.B.I. contributed equally to this work.
